Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $950.00 at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by research analysts at JPMorgan Chase & Co. from $850.00 to $950.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 26.24% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald upped their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday. Oppenheimer restated an “outperform” rating and issued a $865.00 price objective (up previously from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Finally, Scotiabank lifted their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a report on Monday, November 24th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $799.74.

Regeneron Pharmaceuticals Stock Up 1.5%

REGN traded up $11.10 on Monday, reaching $752.55. The company’s stock had a trading volume of 354,676 shares, compared to its average volume of 894,991. The business’s 50 day moving average is $758.39 and its 200 day moving average is $651.29. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11. The stock has a market cap of $79.09 billion, a price-to-earnings ratio of 18.10, a price-to-earnings-growth ratio of 1.92 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.77 and a quick ratio of 4.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $12.07 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of REGN. WPG Advisers LLC grew its stake in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the period. Board of the Pension Protection Fund bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $27,000. Torren Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $38,000. Finally, FNY Investment Advisers LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $38,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat consensus — EPS $11.44 vs $10.74 and revenue $3.88B vs $3.76B; management highlighted steady revenue growth. This earnings beat is the primary catalyst behind analyst revisions and the stock lift. Article Title
• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $865, signaling strong analyst conviction and adding upside to sentiment. Article Title
• Positive Sentiment: Wells Fargo and Cantor Fitzgerald raised price targets to $800 (Wells Fargo moved from $745), and Cantor set an overweight — these upgrades add demand-side support for the stock. Article Title
• Positive Sentiment: Clinical data flow: Regeneron highlighted EYLEA HD® (aflibercept 8 mg) presentations at Angiogenesis 2026, including 64?week QUASAR and Phase 3b ELARA results — positive readthrough for the retinal franchise and future growth prospects. Article Title
• Positive Sentiment: TD Cowen and other outlets raised targets / highlighted Regeneron’s pipeline and recent decision to start paying a dividend — factors that can attract income and growth-focused investors. Article Title
• Neutral Sentiment: Morgan Stanley nudged its target from $768 to $769 and kept an “equal weight” rating — a modest, neutral adjustment that suggests limited near?term change in conviction. Article Title
• Neutral Sentiment: Truist trimmed its target slightly (from $820 to $818) but left a “buy” rating — a small technical tweak without a major signal change. Article Title
• Neutral Sentiment: Commentary pieces note a “valuation gap” vs. pipeline progress and discuss whether REGN looks attractively priced — informative background but less likely to move price than earnings and analyst actions. Article Title

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.